BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc to increase the delivery capabilities of Ionis’ advanced LIgand Conjugated Antisense medicines.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy.

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2021 financial results on Tuesday, July 27, 2021.

ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that it has initiated a Phase I human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.

Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that data from Qu’s RESTORE clinical trial was presented at the 16th Congress of the European Crohn’s and Colitis Organization (ECCO).

Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that the European Patent Office has issued patent number EP3576719B1 covering ADAIR1

Immutep Limited, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 June 2021.

AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, “Retinal organoids on-a-chip: a 3D printed micro-millifluidic bioreactor for long-term retinal organoid maintenance,”

RELIEF THERAPEUTICS Holding AG, NRx Pharmaceuticals, Inc., and Quantum Leap Healthcare Collaborative have announced that they have begun treating patients with inhaled aviptadil in the I-SPY COVID Trial, a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients.